NCI Announces Sites of First Endostatin Phase I Studies
BETHESDA, Md-The first human trials of the antiangiogenesis drug endostatin will take place at the University of Wisconsin-Madison and the University of Texas M.D. Anderson Cancer Center. The National Cancer Institute (NCI), which will sponsor the phase I trials, said that the studies will begin in late summer or early fall. Protocols for the two studies had not been worked out at the time of the NCI’s announcement.
BETHESDA, MdThe first human trials of the antiangiogenesis drug endostatin will take place at the University of Wisconsin-Madison and the University of Texas M.D. Anderson Cancer Center. The National Cancer Institute (NCI), which will sponsor the phase I trials, said that the studies will begin in late summer or early fall. Protocols for the two studies had not been worked out at the time of the NCIs announcement.
Each trial will involve 15 to 25 patients with advanced solid tumors that will include lymphoma and lung, breast, colon, and prostate cancers.
Information on the University of Wisconsin-Madison trial is available by calling 1-800-622-8922 or 608-262-5223. The M.D. Anderson Cancer Center information line is 1-800-392-1611 (select option 3)
Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care
Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.
